Moderna, Inc. (ETR:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
23.63
-0.96 (-3.90%)
At close: Oct 31, 2025
-3.90%
Market Cap9.20B
Revenue (ttm)2.62B
Net Income (ttm)-2.47B
Shares Outn/a
EPS (ttm)-6.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume505
Average Volume39,360
Open24.78
Previous Close24.59
Day's Range23.63 - 24.78
52-Week Range19.89 - 54.20
Beta2.01
RSI53.79
Earnings DateNov 6, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges

Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine...

1 day ago - Investopedia

Moderna (MRNA) Outperforms Broader Market: What You Need to Know

Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

7 days ago - Nasdaq

Notable Friday Option Activity: MRNA, MDB, RKLB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Moderna Inc (Symbol: MRNA), where a total of 91,472 contracts have traded so far, represent...

8 days ago - Nasdaq

UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Rating | MRNA Stock News

UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Rating | MRNA Stock News

8 days ago - GuruFocus

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers...

9 days ago - Wallstreet:Online

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers...

9 days ago - Accesswire

JP Morgan Lowers Price Target for MRNA to $25, Maintains Underweight Rating | MRNA Stock News

JP Morgan Lowers Price Target for MRNA to $25, Maintains Underweight Rating | MRNA Stock News

9 days ago - GuruFocus

December 5th Options Now Available For Moderna (MRNA)

Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA options c...

9 days ago - Nasdaq

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance. ... Full story available on Benzinga.com

9 days ago - Benzinga

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company's investigational cytomegalovirus (CMV) vaccine. CMV is a herpe...

9 days ago - Benzinga

Moderna to Host Investor Event - Analyst Day

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.

9 days ago - Accesswire

Moderna (MRNA) Halts Clinical Development of CMV Vaccine After Trial Results

Moderna (MRNA) Halts Clinical Development of CMV Vaccine After Trial Results

9 days ago - GuruFocus

Moderna (MRNA) Halts CMV Vaccine Program as Late-Stage Trial Falls Short

Moderna (MRNA) Halts CMV Vaccine Program as Late-Stage Trial Falls Short

9 days ago - GuruFocus

Stocks making the biggest moves after hours: IBM, Tesla, Moderna and more

These are the stocks posting the largest moves in extended trading.

10 days ago - CNBC

Moderna ends development of CMV vaccine after trial failure

Moderna said on Wednesday it will discontinue development of its experimental vaccine to prevent cytomegalovirus, a common cause of birth defects, after it failed to meet the main goal of a late-stage...

10 days ago - Reuters

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any ...

10 days ago - Wallstreet:Online

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate an...

10 days ago - Accesswire

Should You Buy Moderna Right Now?

Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.

10 days ago - The Motley Fool

mRNA COVID shots may bolster effects of cancer treatments: study

mRNA-based COVID shots such as those from Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) could lift survival of cancer patients on immunotherapies. Read more here.

11 days ago - Seeking Alpha

Dow Jumps More Than 500 Points Ahead Of Earnings: Investor Fear Eases, Greed Index Remains In 'Fear' Zone

The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the “Fear” zone on Monday. U.S. stocks settled higher on Monday, with the Dow Jones inde...

11 days ago - Benzinga

Monday Sector Leaders: Healthcare, Technology & Communications

Looking at the sectors faring best as of midday Monday, shares of Healthcare companies are outperforming other sectors, higher by 1.5%. Within that group, Moderna Inc (Symbol: MRNA) and Cooper Compani...

12 days ago - Nasdaq

Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News

Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News

12 days ago - GuruFocus

Stock Market Today: S&P 500, Nasdaq, Dow Jones Futures Rise— Micron, Bitmine, Coinbase In Focus

U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher. On Sunday, President Donald Trump again warned that the U.S. economy would face significa...

12 days ago - Benzinga